Firm eyes up £38bn mar­ket

Yorkshire Post - Business - - NEWS -

AVACTA SAID an­ti­bod­ies dom­i­nate mar­kets worth over £38bn de­spite their short­com­ings.

Its Af­fimer tech­nol­ogy has been de­signed to ad­dress many of these neg­a­tive per­for­mance is­sues, in­clud­ing the time taken to gen­er­ate new an­ti­bod­ies, the re­liance on an an­i­mal’s im­mune re­sponse, poor speci­ficity in many cases, and batch to batch variability.

Af­fimer tech­nol­ogy is based on a small pro­tein that can be quickly gen­er­ated to bind with high speci­ficity and affin­ity to a wide range of pro­tein tar­gets.

Avacta has a pre-clin­i­cal biotech de­vel­op­ment pro­gramme with an in-house fo­cus on im­muno-on­col­ogy and bleed­ing dis­or­ders.

Newspapers in English

Newspapers from UK

© PressReader. All rights reserved.